Baxalta Inc (BXLT) : Lipe Dalton scooped up 3,950 additional shares in Baxalta Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 97,205 shares of Baxalta Inc which is valued at $4.1 Million.Baxalta Inc makes up approximately 3.23% of Lipe Dalton’s portfolio.
Other Hedge Funds, Including , Wesbanco Bank Inc reduced its stake in BXLT by selling 24,844 shares or 55.01% in the most recent quarter. The Hedge Fund company now holds 20,319 shares of BXLT which is valued at $861,322. Baxalta Inc makes up approx 0.05% of Wesbanco Bank Inc’s portfolio.Comerica Bank reduced its stake in BXLT by selling 10,807 shares or 5.66% in the most recent quarter. The Hedge Fund company now holds 180,003 shares of BXLT which is valued at $7.6 Million. Baxalta Inc makes up approx 0.07% of Comerica Bank’s portfolio.First Eagle Investment Management reduced its stake in BXLT by selling 2,859,279 shares or 77.18% in the most recent quarter. The Hedge Fund company now holds 845,545 shares of BXLT which is valued at $34.8 Million. Baxalta Inc makes up approx 0.09% of First Eagle Investment Management’s portfolio.Gerber Kawasaki Wealth Investment Management reduced its stake in BXLT by selling 1,900 shares or 6.53% in the most recent quarter. The Hedge Fund company now holds 27,210 shares of BXLT which is valued at $1.1 Million. Baxalta Inc makes up approx 0.78% of Gerber Kawasaki Wealth Investment Management’s portfolio. Schulhoff Co Inc added BXLT to its portfolio by purchasing 5,067 company shares during the most recent quarter which is valued at $212,561. Baxalta Inc makes up approx 0.14% of Schulhoff Co Inc’s portfolio.
Baxalta Inc opened for trading at $44.21 and hit $44.65 on the upside on Friday, eventually ending the session at $44.43, with a gain of 1.62% or 0.71 points. The heightened volatility saw the trading volume jump to 1,35,80,226 shares. Company has a market cap of $30,369,682 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.